Compare Amylx Pharmaceuticals Inc (AMLX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs DENTSPLY SIRONA Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while DENTSPLY SIRONA Inc trades at $11.69 (market cap $2.32B). The key difference: Amylx Pharmaceuticals Inc and DENTSPLY SIRONA Inc are close in size by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | XRAY | |
|---|---|---|
Market Cap | $2.53B | $2.32B |
Sector | Health | Health |
52-Week High | $24.19 | $14.68 |
52-Week Low | $7.82 | $9.64 |
Enterprise Value | $2.28B | $4.40B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
DENTSPLY SIRONA (XRAY) trades at $12.12, down 7.97% in 24 hours, with a bearish technical signal and support near $12. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Financials show negative net income margins and ROE, though gross margins remain solid at 49.52%. Recent news highlights institutional stake increases and strategic partnerships, such as the expanded Medline Sinclair relationship in Canada.
The outlook is cautious due to persistent revenue declines and profitability challenges, offset by cost-cutting efforts and digital dentistry growth. Risks include weak European demand and high debt levels, while analyst consensus is Hold with a $11.50 price target, indicating limited near-term upside amid turnaround execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
